Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-10
2006-01-10
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S311000, C514S314000, C514S585000, C514S595000, C514S596000, C514S357000, C514S396000, C546S139000, C546S143000, C546S159000, C546S176000, C564S026000, C564S047000, C564S048000
Reexamination Certificate
active
06984647
ABSTRACT:
This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to β-aminotetralin-derived ureas that are potent antagonists or agonists of VR1 which are useful for the treatment and prevention of inflammatory and other pain conditions in mammals.
REFERENCES:
patent: 6140354 (2000-10-01), Dax et al.
patent: 6169116 (2001-01-01), Swoboda
patent: 6201025 (2001-03-01), Dax et al.
patent: 2003/0158188 (2003-08-01), Lee et al.
patent: 2003/0158198 (2003-08-01), Lee et al.
patent: 2003/0236280 (2003-12-01), Codd et al.
patent: 0 064 964 (1984-08-01), None
patent: 335375 (1989-10-01), None
patent: WO 00/51970 (2000-09-01), None
patent: WO 02/16317 (2002-02-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02/16319 (2002-02-01), None
patent: WO 02/082212 (2002-10-01), None
patent: WO 03/014064 (2003-02-01), None
patent: WO 03/049702 (2003-06-01), None
patent: WO 03/059904 (2003-07-01), None
patent: WO 03/062209 (2003-07-01), None
patent: WO 03/068749 (2003-08-01), None
Bamberger, E. et al. “Ueber beta-tetrahydrophtylamin”.Chem. Ber., 1988, pp. 847-860, vol. 21, XP009016746.
Agrawal, K.C., et al., “Potential Antitumor Agents. A Series of 5-Substituted 1-Formylisoquinoline Thiosemicarbazones,”J. Med Chem., 1968, pp. 700-703, vol. 11.
Sims, J.J.; et al., “Improvenent of AB-Tetralone Synthesis: 5-, 6-, 7-and 8-Methyl-B-Tetralones,”Tetrahedron Letters, 1971, pp. 951-954, No. 14.
Walpole, C.S.J. et al., “The Discovery of Capsazepine, the First Competitive Antagonist of the Sensory Neuron Excitants Capasaicin and Resiniferatoxin,”J. Med. Chem., 1994, pp. 1942-1954, vol. 37.
Garcia-Martinez, C. et al., “Attenuation of Thermal Nociception and Hyperalgesia by VRI Blockers,”PNAS, 2002, pp. 2374-2379, vol. 99, No. 4.
Grant, E.R., “Simultaneous Intracellular Calcium and Sodium Flux Imaging in Human Vanilloid Receptor 1 (VR1)-Transfected Human Embryonic Kidney Cells: A Method to Resolve Ionic Dependence of VR1-Mediated Cell Death,”J. Pharm. Research Inst., 2002, pp. 9-17, vol. 300, No. 1.
PCT International Search Report dated Sep. 17, 2003 for PCT Application No. PCT/US 03/15254 which relates to U.S. Appl. No. 10/438,477 filed herewith.
Dax Scott L.
Jetter Michele
McDonnell Mark
McNally James J.
Youngman Mark
Davis Zinna Northington
Janssen Pharmaceutica N.V.
Zisk Matthew Bruce
LandOfFree
Aminotetralin-derived urea modulators of vanilloid VR1 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminotetralin-derived urea modulators of vanilloid VR1 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminotetralin-derived urea modulators of vanilloid VR1 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3533626